Amplifications in the EGFR gene are detected in 57.4% of primary GBM patients, leading to high levels of EGFR protein and it has been observed that amplifications of the EGFR are retained in recurrent gliomas [22]. This evidence concerns the gene EGFR and central nervous system cancer.